<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3509">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04780581</url>
  </required_header>
  <id_info>
    <org_study_id>MP3-pulses-COVID-19</org_study_id>
    <nct_id>NCT04780581</nct_id>
  </id_info>
  <brief_title>Glucocorticoid Therapy in Coronavirus Disease COVID-19 Patients</brief_title>
  <official_title>MP3-pulses-COVID-19. Methylprednisolone Pulses Versus Dexamethasone According RECOVERY Protocol in Patients With Pneumonia Due to SARS-COV-2 Coronavirus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Investigación Biomédica de Salamanca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment with glucocorticoids in COVID patients. Low-intervention, phase IV, open-label,&#xD;
      randomised, low-intervention clinical trial comparing 2 active treatments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of high-dose bolus glucocorticoids in the treatment of patients with COVID-19&#xD;
      infection will increase the anti-inflammatory effect without increasing side effects. This&#xD;
      will allow a better patient outcome, reducing the number of deaths and the need for&#xD;
      intubation or admission to the Intensive Care Unit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open-label, randomised clinical trial comparing 2 active treatments.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality rate in COVID-19 patients after high-dose methylprednisolone bolus administration versus mortality rate intermediate-dose dexamethasone pattern (RECOVERY trial)</measure>
    <time_frame>28 days</time_frame>
    <description>Mortality rate (percentage)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Admission in Intensive Unit Care (ICU)</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of ICU admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of respiratory support requirements</measure>
    <time_frame>28 days</time_frame>
    <description>Proportion of patients (number of cases with respiratory support requirement / total number of patients) with non-invasive mechanical ventilation and/or high-flow oxygen requirements.&#xD;
Proportion of patients (number of cases with respiratory support requirement / total number of patients) with invasive mechanical ventilation or intubation requirements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days in hospital</measure>
    <time_frame>28 days</time_frame>
    <description>Number of days in hospital from the star of the treatment until discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of presence of adverse events related with use of high dose of glucocorticoids.</measure>
    <time_frame>28 days</time_frame>
    <description>Presence or absence of adverse effects (infections, hyperglycaemia, psychotic states or other adverse effects).&#xD;
Incidence of infections, hyperglycaemia, psychotic states or other adverse effects, if applicable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of other immunosuppressors requirements.</measure>
    <time_frame>28 days</time_frame>
    <description>Occurrence of use of other immunosuppressors (active substance, dose, duration, if applicable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Status according to the World Health Organization (WHO) 10-category scale.</measure>
    <time_frame>3 months</time_frame>
    <description>Clinical evaluation of patient status according to the WHO 10-category scale.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">290</enrollment>
  <condition>Corona Virus Infection</condition>
  <arm_group>
    <arm_group_label>RECOVERY</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intermediate-dose dexamethasone (6mg/24h - 10 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BOLUS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high-dose methylprednisolone bolus (250mg/4h - 3 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>6 mg/24h - 10 days</description>
    <arm_group_label>RECOVERY</arm_group_label>
    <other_name>Recovery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>250 mg/ 24h - 3 days</description>
    <arm_group_label>BOLUS</arm_group_label>
    <other_name>Bolus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Over 18 years of age&#xD;
&#xD;
          2. Inpatient&#xD;
&#xD;
          3. Diagnosis of SARS-CoV-2 infection confirmed by reverse transcriptase polymerase chain&#xD;
             reaction (RT-PCR) or antigen&#xD;
&#xD;
          4. They present evidence in computerized axial tomography (CT) of pulmonary involvement&#xD;
             attributed to the infection by COVID. Patients in whom CT scans are not performed must&#xD;
             have suspected pulmonary involvement by clinical examination with simple compatible or&#xD;
             suggestive radiology.&#xD;
&#xD;
          5. Requires supplementary oxygen due to basal saturation ≤ 93% (with ambient O2, 21%)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The patient's situation is so serious that the doctor in charge thinks he could die&#xD;
             within 24 hours.&#xD;
&#xD;
          2. At the time of randomisation, patients require one of the following 4 ventilatory&#xD;
             supports:&#xD;
&#xD;
               1. high-flow oxygen devices.&#xD;
&#xD;
               2. non-invasive mechanical ventilation.&#xD;
&#xD;
               3. invasive mechanical ventilation.&#xD;
&#xD;
               4. Extracorporeal membrane oxygenation (ECMO).&#xD;
&#xD;
          3. The patient is or has been treated in the 2 weeks prior to randomisation with&#xD;
             glucocorticoids or inflammation modifying drugs, both conventional (thiopurines,&#xD;
             cyclophosphamide, cyclosporine, tacrolimus), leflunomide, methotrexate, mycophenolate&#xD;
             mofetil/mycophenolic acid, sulfasalazine, hydroxychloroquine or chloroquine) as&#xD;
             synthetics or biologics directed against therapeutic targets (abatacept, belimumab,&#xD;
             CD-20, IL1, IL6, Il12. 23, IL-23, Il.17, TNF, integrin α4β7 or Janus kinase inhibitors&#xD;
             JAK). Patients who are only on maintenance treatment with doses of steroids less than&#xD;
             or equal to 7.5 mg of prednisone or equivalent per day will not be excluded.&#xD;
&#xD;
          4. The patient is pregnant or breastfeeding.&#xD;
&#xD;
          5. The patient has a chronic renal disease is stage 4 or 5 (CCr &lt;30 ml/min).&#xD;
&#xD;
          6. Moderate to severe dementia at the investigator's discretion.&#xD;
&#xD;
          7. Hypersensitivity to any of the active ingredients or to any of the excipients included&#xD;
             in its formulation.&#xD;
&#xD;
          8. Untreated systemic infections not caused by COVID-19.&#xD;
&#xD;
          9. Active stomach or duodenal ulcer.&#xD;
&#xD;
         10. Recent vaccination with live vaccines.&#xD;
&#xD;
         11. Other infection or disease that explains the lung disorder.&#xD;
&#xD;
         12. Inability of the patient to understand the study or to sign the informed consent&#xD;
             unless consent is delegated to a legal representative.&#xD;
&#xD;
         13. Active participation in another clinical study in the last 15 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis Corral Gudino</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luis Corral Gudino</last_name>
    <phone>983 420400</phone>
    <email>lcorral@saludcastillayleon.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Esperanza López Franco</last_name>
    <phone>923 291100</phone>
    <email>esperanza.lopez@scren.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de Burgos</name>
      <address>
        <city>Burgos</city>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>María López Veloso</last_name>
      <email>mlopezvel@saludcastillayleon.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de León</name>
      <address>
        <city>León</city>
        <zip>24071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Ignacio Martín González</last_name>
      <email>jmartingo@saludcastillayleon.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Iván Cusácovich Torres</last_name>
      <email>icusacovich@saludcastillayleon.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Río Hortega</name>
      <address>
        <city>Valladolid</city>
        <zip>47012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Corral Gudino</last_name>
      <email>lcorral@saludcastillayleon.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 15, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

